• Medical News
    EFFISAYIL 2: Spesolimab Associated with Long-Term GPP Relief

    Patients with generalized pustular psoriasis (GPP) experienced sustained symptom control and quality of life (QoL) improvements when treated with spesolimab, according to an analysis of results from the EFFISAYIL 2 trial. 

    Researchers on the randomized, placebo-controlled EFFISAYIL 2 trial evaluated...

    05/26/2025
  • psoriasis treatment and residual inflammation cardiovascular risk
    Medical News
    Psoriasis Treatment and Residual Inflammation: Evaluating Cardiovascular Risk a…
    05/22/2025
  • dietary choices and psoriasis role of upf
    Medical News
    Dietary Choices and Psoriasis: The Role of Ultra-Processed Foods
    05/08/2025
  • ultra processed foods psoriasis risk
    Medical News
    Ultra-Processed Foods: Dietary Impact on Psoriasis Risk
    05/06/2025
  • advertisement
  • Medical News
    EARLY: Guselkumab Use Supported in PsO Patients With HBV, Cancer, or Heart Disease

    Key Takeaways:

    • Guselkumab did not cause reactivation of HBV, HCV, LTBI, or HIV during long-term follow-up.

    • Patients with active or historical cancer safely received guselkumab regardless of cancer risk classification.

    • Cardiovascular comorbidities did not impact guselkumab’s safety profile.

     

    Guselkumab, an IL-23 inhibitor approved for moderate-to-severe psoriasis, showed long-term safety in patients with complex comorbidities—including chronic infections, prior malignancies, and cardiovas...

    04/25/2025
  • comparative effectiveness psoriasis
    Medical News
    Comparative Effectiveness: Adalimumab Biosimilars versus Humira in Psoriasis
    04/18/2025
  • Medical News
    Biologic Costs for Plaque Psoriasis Doubled Since 2007, Study Finds

    Key Takeaways

    • Average net cost of first-line biologic treatment for plaque psoriasis rose 122% from 2007 to 2021.

    • Most 2021 patients began treatment with high-cost IL-23 or IL-17 inhibitors despite similar efficacy among lower-cost options.

    • Researchers say aligning biologic selection with the ...

     

    A new analysis shows the average net annual cost of first-line biologic treatments for plaque psoriasis more than doubled between 2007 and 2021, rising from $21,236 to $47,125.

    The study researchers, ...

    04/17/2025
  • Medical News
    Review Unpacks Safety Data in Psoriasis Trials

    Key Takeaways

    • Safety data in psoriasis trials are often inconsistently collected and reported, limiting clinical utility.

    • Exposure-adjusted incidence rates (EAIRs) provide accurate assessment, but need careful interpretation.

    • Comparing adverse event rates to psoriasis-specific registries and t...

     

    While clinical trials frequently emphasize efficacy, safety data often remain inconsistently analyzed and underreported, according to the authors of a new review in the Journal of Clinical and Aesthet...

    04/16/2025
  • Medical News
    ICONIC-LEAD: Oral Icotrokinra Clears Skin in 75% of Adolescents with Plaque Psoriasis

    Key Takeaways

    • 75% of adolescents achieved completely clear skin with icotrokinra by week 24 in the ICONIC-LEAD study.

    • Icotrokinra had a favorable safety profile with fewer adverse events than placebo.

     

    Icotrokinra, an investigational oral IL-23 receptor antagonist, led to completely clear skin in 75% of adolescents with moderate-to-severe plaque psoriasis by week 24, according to results presented a...

    04/11/2025
  • Medical News
    Study Links Psoriasis Gene Regulation to Spatial Genome Changes

    Key Takeaways

    • CD4+ T cells in psoriasis show altered architecture that researchers said correlates with immune gene dysregulation.

    • Disrupted topologically associated domains (TAD)s and loop dynamics affect expression of LYN, YBX3, and other immune genes.

    • Psoriasis-associated SNPs may act to mo...

     

    Results from a new study in the Journal of Investigative Dermatology showed how changes in the 3D chromatin architecture of CD4+ T cells contribute to immune dysregulation in psoriasis.

    "In this study...

    04/08/2025
  • advertisement
  • Medical News
    Obesity and Epidermal Innate Immunity Linked to Resistance to Biologic Therapy in Psoriasis

    Key Takeaways

    • Overweight psoriasis patients had a 17-fold higher risk of resistance to biologic therapy.

    • Innate immune dysregulation and neutrophilic inflammation in the epidermis may undermine biologic efficacy.

    • Current biologics may need to be complemented by therapies targeting epidermal in...

     

    Patients with severe plaque psoriasis who are overweight are more likely to experience resistance to biologic therapies, according to new findings

    The study researchers designed and conducted a cross-...

    04/03/2025
  • Medical News
    Researchers Identify Novel IL-17A-Linked Psoriasis Gene and Therapeutic Target

    Machine learning and in vivo experimentation have identified three genes strongly linked to IL-17A-mediated inflammation in psoriasis, according to new research published in Scientific Reports.

    "It is widely acknowledged that Th17/IL-17A axis plays a key role in the pathogenesis of psoriasis," th...

    04/03/2025
  • diversity clinical trials psoriasis research
    Medical News
    Diversity in Clinical Trials: Innovative Recruitment Strategies for Psoriasis R…
    jamanetwork.com
    04/01/2025

    • Program Chapters

    Segment Chapters

    Playlist:

    advertisement

    Recommended

    Register

    We’re glad to see you’re enjoying ReachMD…
    but how about a more personalized experience?

    Register for free
    PrevNext